Gruss & Co Has Boosted Valeant Pharmaceuticals Intl (VRX) Stake; Monotype Imaging Holdings (TYPE)’s Sentiment Is 1.53

December 4, 2017 - By Nellie Frank

Monotype Imaging Holdings Inc. develops, markets, and licenses technologies and fonts in the United States, the United Kingdom, Germany, Japan, and rest of Asia. The company has market cap of $1.01 billion. The firm offers font products, including its own fonts from the Monotype Libraries, as well as fonts from third parties through its e-commerce Websites, including myfonts.com, fonts.com, fontshop.com, and linotype.com. It has a 874.14 P/E ratio. It also provides font scaling engine and font compression technologies that are compatible with virtually font formats and industry standards, including the PostScript and PCL printing languages; font solutions for consumer device manufacturers, including Edge and SmartHint technologies for precise pixel adjustments to enable fonts to display with optimal quality in suboptimal display environments; printer driver kits; and fonts for printer manufacturers.

Gruss & Co Inc increased Valeant Pharmaceuticals Intl (VRX) stake by 223.4% reported in 2017Q2 SEC filing. Gruss & Co Inc acquired 21,000 shares as Valeant Pharmaceuticals Intl (VRX)’s stock declined 15.71%. The Gruss & Co Inc holds 30,400 shares with $526,000 value, up from 9,400 last quarter. Valeant Pharmaceuticals Intl now has $6.01B valuation. The stock increased 2.99% or $0.5 during the last trading session, reaching $17.25. About 17.37M shares traded or 34.54% up from the average. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has declined 48.51% since December 4, 2016 and is downtrending. It has underperformed by 65.21% the S&P500.

Gruss & Co Inc decreased Schlumberger Ltd (NYSE:SLB) stake by 22,000 shares to 5,000 valued at $329,000 in 2017Q2. It also reduced Microsoft Corp (NASDAQ:MSFT) stake by 10,000 shares and now owns 13,200 shares. W P Carey Inc (NYSE:WPC) was reduced too.

Investors sentiment decreased to 1.08 in 2017 Q2. Its down 0.16, from 1.24 in 2017Q1. It is negative, as 53 investors sold VRX shares while 76 reduced holdings. 49 funds opened positions while 90 raised stakes. 171.89 million shares or 1.47% more from 169.41 million shares in 2017Q1 were reported. The New York-based First Manhattan Co has invested 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). 175,534 are held by Balyasny Asset Limited Com. 1832 Asset Management Limited Partnership has 550,944 shares. Tower Cap Limited Liability Com (Trc) stated it has 0% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Alphamark Advsrs Ltd Limited Liability Company has invested 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Integral Derivatives Ltd Llc stated it has 0.01% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Tb Alternative Assets reported 1.98% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Iron Fincl Ltd Co accumulated 11,894 shares. Ipg Invest Advisors Ltd Llc has 11,750 shares. Community Tru Com accumulated 25,095 shares or 0.05% of the stock. Winfield Assoc reported 85 shares or 0% of all its holdings. Citadel Limited Liability Co reported 453,718 shares stake. Dimensional Fund Advsr LP owns 1.05 million shares. Deutsche Commercial Bank Ag reported 1.44 million shares or 0.02% of all its holdings. First Allied Advisory Ser Inc has 16,465 shares.

Among 27 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 6 have Buy rating, 3 Sell and 18 Hold. Therefore 22% are positive. Valeant Pharmaceuticals Intl had 144 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Wells Fargo on Monday, July 17 with “Sell”. The company was maintained on Wednesday, March 16 by RBC Capital Markets. The firm earned “Buy” rating on Monday, September 25 by Cantor Fitzgerald. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, June 29. The firm earned “Neutral” rating on Thursday, December 17 by Mizuho. The firm has “Buy” rating given on Wednesday, November 11 by Stifel Nicolaus. Piper Jaffray maintained the stock with “Underweight” rating in Wednesday, January 4 report. The company was maintained on Monday, October 16 by Jefferies. RBC Capital Markets maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Friday, May 5 with “Sector Perform” rating. The rating was maintained by Deutsche Bank with “Hold” on Monday, November 14.

Analysts await Monotype Imaging Holdings Inc. (NASDAQ:TYPE) to report earnings on February, 16. They expect $0.04 earnings per share, down 42.86% or $0.03 from last year’s $0.07 per share. TYPE’s profit will be $1.60 million for 158.44 P/E if the $0.04 EPS becomes a reality. After $0.03 actual earnings per share reported by Monotype Imaging Holdings Inc. for the previous quarter, Wall Street now forecasts 33.33% EPS growth.

The stock increased 0.60% or $0.15 during the last trading session, reaching $25.35. About 307,390 shares traded. Monotype Imaging Holdings Inc. (TYPE) has declined 15.71% since December 4, 2016 and is downtrending. It has underperformed by 32.41% the S&P500.

Trigran Investments Inc. holds 8.66% of its portfolio in Monotype Imaging Holdings Inc. for 1.85 million shares. Rgm Capital Llc owns 3.43 million shares or 6.39% of their US portfolio. Moreover, Kayne Anderson Rudnick Investment Management Llc has 0.77% invested in the company for 4.23 million shares. The Massachusetts-based Granahan Investment Management Inc Ma has invested 0.45% in the stock. Punch & Associates Investment Management Inc., a Minnesota-based fund reported 251,012 shares.